Last reviewed · How we verify
NCT05111860
Neoadjuvant Bevacizumab + Chemotherapy Combined With Short-course Radiotherapy
Phase 1, PHASE2 trial testing Bevacizumab+mFOLFOX6 in Neoadjuvant Treatment in 20 participants. Status unknown.
1 August 2024
Quick facts
| Lead sponsor | Shanghai Minimally Invasive Surgery Center |
|---|---|
| Phase | Phase 1, PHASE2 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 20 |
| Start date | 1 November 2022 |
| Primary completion | 1 August 2024 |
| Estimated completion | 1 August 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Bevacizumab+mFOLFOX6 — full drug profile →
Conditions studied
- Neoadjuvant Treatment — all drugs for Neoadjuvant Treatment →
- Rectal Cancer — all drugs for Rectal Cancer →
- Bevacizumab — all drugs for Bevacizumab →
- Radiotherapy — all drugs for Radiotherapy →
Sponsor
Shanghai Minimally Invasive Surgery Center — full company profile →
Who can join
Adults 18 to 75, any sex, with Neoadjuvant Treatment or Rectal Cancer. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Prospectively Investigate the effectiveness and safety of neoadjuvant Bevacizumab + chemotherapy (mFOLFOX6) combined with short-course radiotherapy (25Gy/5Fx) for RAS mutant-type locally advanced rectal cancer
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05111860
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neoadjuvant Treatment
Currently open trials in the same condition.
- NCT06959511 — Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery · Phase 2 · recruiting
- NCT05524012 — Longitudinal Multimodal Response Assessment During Neoadjuvant Treatment of Rectal Cancer · active not recruiting
- NCT05382052 — Study of ctDNA as Prognostic Factor on Resectable Stage IIIA NSCLC Patients Treated With Neoadjuvant Treatment · active not recruiting
- NCT05343325 — The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC · Phase 2 · recruiting
- NCT04280822 — Neo-adjuvant Immunochemotheray Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Carcinoma · Phase 3 · recruiting
Other Shanghai Minimally Invasive Surgery Center trials
Trials by the same sponsor.
- NCT07076979 — Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Gastric Cancer：MetB · recruiting
- NCT07068529 — Development and Validation of Metabolic Biomarkers for Early Diagnosis, Prognosis, and Recurrence of Colorectal Cancer：M · recruiting
- NCT06746298 — A Prospective Study of Expression Profiling-based Assessment of the Efficacy of Neoadjuvant Therapy for Rectal Cancer · not yet recruiting
- NCT04620473 — Anlotinib Hydrochloride Combined With Capeox in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer · Phase 2 · withdrawn
- NCT05495048 — Transvaginal NOSES Versus Conventional Laparoscopic Surgery for Right Hemicolectomy · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05111860 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Shanghai Minimally Invasive Surgery Center
- Last refreshed: 7 March 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05111860.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing